FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...